Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Biologic Opens New Plasma Collection Station As China’s Blood Product Reforms Have Closed Doors For Many Competitors

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China Biologic Products began operations at its new plasma collection station in Qihe County, Shandong Province, the company announced July 9, increasing its annual supply of plasma from 60 to 80 metric tons to 100 metric tons

You may also be interested in...



China Blood Products Market Increases Steadily, Driven By Increased Price And Government's Stricter Supervision

SHANGHAI - The sale of blood products in China reached $3.966 billion in 2008 with an annual growth rate 12.23 percent, according to consulting company Draco Healthcare. The growth will continue in the future, driven by increasing demand, limited supply and higher prices

China Blood Products Market Increases Steadily, Driven By Increased Price And Government's Stricter Supervision

SHANGHAI - The sale of blood products in China reached $3.966 billion in 2008 with an annual growth rate 12.23 percent, according to consulting company Draco Healthcare. The growth will continue in the future, driven by increasing demand, limited supply and higher prices

China Biologic Renews GMP Certification Under Stiffer SFDA GMP Rules

SHANGHAI- China Biologic Products has renewed its GMP certification for its production facility in Taian City in compliance with China State FDA's new, strict GMP standards, which took effect in January

UsernamePublicRestriction

Register

ID1132380

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel